RBC Capital Maintains Outperform on Korro Bio, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Korro Bio (NASDAQ:KRRO) and raised the price target from $95 to $105.

October 21, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its positive outlook on Korro Bio by maintaining an 'Outperform' rating and increasing the price target from $95 to $105, indicating confidence in the company's future performance.
The increase in the price target from $95 to $105 by RBC Capital suggests a positive outlook on Korro Bio's future performance. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100